Cure ETF – Buy

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

Qube Holdings – Buy

Qube Holdings is under Algo Engine buy conditions.

Port volumes for April & May were stronger than analysts expected which adds support to the $3.50 price target for Qube.

Total container movements across Australia’s major ports have increased +11% compared to the same time last year.

China ETF – IZZ

ASX:IZZ is under Algo Engine buy conditions. We expect buying interest to increase within the $55 – $60 price range.

Traders may wait for the third factor to align, an upturn in the momentum indicators. Watch for the stochastic to move higher or the price action on the main chart to cross above the 10-day average.

21/5 Buy IZZ

31/5 IZZ remains above the 10 day average.

Cure ETF – Buy

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

Inghams Group – FY21 Upgrade

Inghams Group is now under Algo Engine buy conditions following recent signals within the $3.10 to $3.30 price range.

The rally in the share price on Friday was the result of the company upgrading FY21 guidance to EBITDA 203-$213m (statutory $438-448m) and NPAT to be $96-103m.

We have ING trading on a forward yield of 5% and we expect to see mid-single-digit EPS growth over the next 2 – 3 years.